Literature DB >> 16416130

Effect of previous argon laser trabeculoplasty on the ocular hypotensive action of latanoprost.

Esther Arranz-Marquez1, Miguel A Teus.   

Abstract

PURPOSE: To study the effect of previous argon laser trabeculoplasty (ALT) on the hypotensive activity of latanoprost in primary open-angle glaucoma (POAG).
METHODS: This was a prospective, observer-masked study. We measured the intraocular pressure (IOP) before and after 3 months of monotherapy with latanoprost in 43 eyes that had undergone a previous ALT, and in a control group (not treated with ALT) of 43 IOP-matched eyes with POAG.
RESULTS: Latanoprost induced a 17.4+/-16.6% IOP decrease in the study group (ALT-treated eyes) and a 25.8+/-17.2% IOP reduction in the control eyes (P=0.02, unpaired Student's t-test).
CONCLUSIONS: Latanoprost is less effective in ALT-treated eyes than in eyes with POAG not treated with ALT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16416130     DOI: 10.1007/s00417-005-0198-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  16 in total

Review 1.  The extracellular matrix and its modulation in the trabecular meshwork.

Authors:  B Y Yue
Journal:  Surv Ophthalmol       Date:  1996 Mar-Apr       Impact factor: 6.048

2.  Delayed response to argon laser trabeculoplasty in monkeys. Morphological and morphometric analysis.

Authors:  S Melamed; J Pei; D L Epstein
Journal:  Arch Ophthalmol       Date:  1986-07

3.  Laseropuncture of anterior chamber angle in glaucoma.

Authors:  M M Krasnov
Journal:  Am J Ophthalmol       Date:  1973-04       Impact factor: 5.258

4.  Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.

Authors:  C B Camras
Journal:  Ophthalmology       Date:  1996-01       Impact factor: 12.079

5.  Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork.

Authors:  D E Parshley; J M Bradley; J R Samples; E M Van Buskirk; T S Acott
Journal:  Curr Eye Res       Date:  1995-07       Impact factor: 2.424

6.  Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

Authors:  P G Watson
Journal:  Ophthalmology       Date:  1998-01       Impact factor: 12.079

7.  Latanoprost for uncontrolled glaucoma in a compassionate case protocol.

Authors:  B Patelska; D S Greenfield; J M Liebmann; M Wand; H Kushnick; R Ritch
Journal:  Am J Ophthalmol       Date:  1997-09       Impact factor: 5.258

8.  Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

Authors:  C B Camras; A Alm; P Watson; J Stjernschantz
Journal:  Ophthalmology       Date:  1996-11       Impact factor: 12.079

9.  Aqueous prostaglandin E2 and intraocular pressure after argon laser trabeculoplasty in glaucoma patients pretreated with topical piroxicam.

Authors:  M T Dorigo; D Doro; A Cecchinato
Journal:  Int J Tissue React       Date:  1987

10.  Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.

Authors:  Najam A Sharif; Curtis R Kelly; Julie Y Crider
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-02       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.